Business Context and Reporting Period
This Form 8-K is filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on November 15, 2022. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the closing bid price of the company's common stock, which reached $1.00 per share or greater during the compliance period.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5450(a)(1). Previously, on July 18, 2022, the company received notice of non-compliance because its stock price had been below $1.00 for 30 consecutive business days. As of November 14, 2022, the company regained compliance after maintaining a closing bid price of at least $1.00 for 10 consecutive business days (October 31 to November 11, 2022).
Guidance, Outlook, and Risks
Management commentary indicates that no further action is required by the company regarding the Minimum Bid Requirement. The filing does not contain forward-looking guidance, risk factors, contingencies, or unusual items beyond the resolution of the listing deficiency.
Investor Verification Checklist
- Verify the company name is Aeglea BioTherapeutics, Inc. (Ticker: AGLE), not Spyre Therapeutics.
- Confirm the stock price has remained above the $1.00 threshold to maintain Nasdaq listing status.
- Note that this filing resolves a prior deficiency notice issued in July 2022.
- Check subsequent filings for any new listing compliance issues or financial updates.